Comparing itraconazole and posaconazole for chronic lung fungus
Treatments studied
Part of Infections clinical trials.
This study compares two antifungal medications (itraconazole and posaconazole) to see which works better for a chronic fungal lung infection called aspergillosis. If you have this condition, taking part may help control your symptoms and improve your quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had symptoms like a lingering cough, coughing up blood, weight loss, or fever for at least 3 months.
- A CT scan of your chest must show holes (cavities) or other long-term changes typical of fungal infection.
- A blood test, sputum sample, or bronchoscopy must show signs of the Aspergillus fungus.
- You must not have active tuberculosis, lung cancer, or another active infection that could explain your symptoms.
- You must not have taken itraconazole, posaconazole, or similar drugs in the last 3 months.
- You must not be on high-dose steroids or have HIV, and you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares itraconazole taken by mouth alone versus itraconazole plus steroid pills in people who have a mix of two Aspergillus lung conditions. It aims to see which approach works better to control symptoms and lung changes caused by Aspergillus infection.
This study compares two inhaled treatments (amphotericin B vs. saline) to see which one works better as maintenance therapy for people with chronic pulmonary aspergillosis. It aims to find a convenient way to keep the infection under control after initial treatment.
This study tests whether a combination of inhaled liposomal amphotericin B (Ambisome) plus itraconazole works better for chronic pulmonary aspergillosis (CPA). It may help control long-term Aspergillus lung infection and symptoms.
This study will use special scans to see how an inhaled antifungal medicine (amphotericin B) reaches the lungs in people with chronic pulmonary aspergillosis. The results may help doctors choose better treatments in the future.
This trial compares three treatments for ABPA: a steroid (prednisolone), an antifungal (itraconazole), or both together. It aims to find which works best for controlling symptoms and preventing flare-ups.
This Mayo Clinic study tests whether the oral antifungal drug itraconazole can help people with bronchiectasis who have mold growing in their airways. The goal is to see if it improves symptoms and reduces mold in the lungs.
Hear when a new Chronic Pulmonary Aspergillosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.